We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+24.28%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$209M
AUM Growth
+$46.7M
Cap. Flow
+$19.2M
Cap. Flow %
9.19%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$19.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$93.2M 44.51%
1,887,478
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$75.8M 36.21%
2,067,861
– –
MRUS
3
DELISTED
Merus
MRUS
$19.2M 9.17%
1,600,000
– –
CMPI
4
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$17.3M 8.25%
+1,501,716
New +$19.2M
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.89M 1.86%
1,570,000
– –

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q3 2020 Portfolio in Review

As of Q3 2020, Medicxi Ventures Management held 5 positions worth $209M, up 29% from $163M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management deployed $19.2M of net new capital in Q3 2020, opening 1 new position. Its largest new stake was Checkmate Pharmaceuticals, Inc. Common Stock: 1,501,716 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's largest Q3 2020 buy was Checkmate Pharmaceuticals, Inc. Common Stock: 1,501,716 shares worth $17.3M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $209M portfolio in Q3 2020.
  • Medicxi Ventures Management opened 1 new position and closed 0 in Q3 2020.
  • Medicxi Ventures Management's portfolio value rose 29% quarter-over-quarter to $209M.

Based on Medicxi Ventures Management's 13F filing for Q3 2020, filed 27 Oct 2020.